By: Beatrisa Popovitz, Senior Staff Editor – On January 31st 2014, the FDA announced the release of a revolutionary new drug, tasimelteon (Hetlioz®). Tasimeleton is the first developed treatment of non-24-hour sleep-wake cycle syndrome in blind individuals.1 Formulated by Vanda Pharmaceuticals Inc., this melatonin receptor agonist works by binding to and activating the MT1 and…

By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen…

By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the…

By: Addolorata Ciccone, Pharm.D. Candidate c/o 2013 – The following medications are easily confused.  Try to match each one with its corresponding fun fact.  This capsule should be swallowed whole; if chewed or dissolved orally, oropharyngeal anesthesia may occur, which poses a choking hazard.  Drinking a glass of water can help bypass this potential adverse…

By: Mohamed Dungersi & Mahdieh Danesh Yazdi, Associate Student Editors – Each month, the editors at the Rho Chi Post have the opportunity to interview one or more of our faculty members. This month, we had the tremendous opportunity to interview the dean of St. John’s University College of Pharmacy and Allied Health Professions, Dean…